BioCryst Pharmaceuticals (BCRX) News Today $9.02 +0.02 (+0.22%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$8.98 -0.04 (-0.44%) As of 07/2/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is BioCryst Pharmaceuticals Up Today?Toggle Visibility of Why Is BioCryst Pharmaceuticals Up Today?BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw its shares move today after several analyst updates swung between upbeat price-target hikes and a modest cut to its near-term EPS outlook. Key drivers: Positive Sentiment: Wedbush raised its Q1 2026 EPS forecast for BioCryst from $0.11 to $0.18 and maintained an Outperform rating with an $18 price objective. Wedbush Issues Positive Outlook for BCRX Earnings Positive Sentiment: Bank of America lifted its price target on BioCryst from $13 to $15 and kept a Buy rating, citing upside potential. Bank of America Boosts BioCryst Pharmaceuticals Price Target to $15.00 Positive Sentiment: Royal Bank of Canada assigned an Outperform rating to BioCryst, reinforcing confidence in the stock’s long-term prospects. BioCryst Pharmaceuticals Given “Outperform” Rating at Royal Bank Of Canada Negative Sentiment: Cantor Fitzgerald trimmed its FY2025 EPS estimate for BioCryst from $0.09 to $0.06, though it kept an Overweight rating and a $20 target price. Cantor Fitzgerald Issues Negative Outlook for BCRX Earnings Overall, bullish price-target revisions from Wedbush, Bank of America and RBC may support the shares, while Cantor Fitzgerald’s EPS cut introduces some caution on the FY2025 outlook.Posted 9h agoAI Generated. May Contain Errors. BCRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Wedbush Has Positive Outlook for BCRX Q1 Earnings4 hours ago | americanbankingnews.comWedbush Issues Positive Outlook for BCRX EarningsJuly 2 at 8:44 AM | marketbeat.comBank of America Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $15.00July 2 at 3:19 AM | americanbankingnews.comFY2025 EPS Estimates for BCRX Lowered by Cantor FitzgeraldJuly 2 at 2:12 AM | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $18.00 Price Target at WedbushJuly 2 at 2:33 AM | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $15.00July 1 at 10:34 AM | marketbeat.comCantor Fitzgerald Issues Negative Outlook for BCRX EarningsJuly 1 at 7:34 AM | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Outperform" Rating at Royal Bank Of CanadaJuly 1 at 2:56 AM | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.5% - What's Next?June 30 at 3:57 PM | marketbeat.comBioCryst Pharmaceuticals' (BCRX) Outperform Rating Reiterated at Royal Bank Of CanadaJune 30 at 10:34 AM | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Wedbush Analyst SaysJune 30 at 8:55 AM | marketbeat.comBioCryst Pharmaceuticals is Now Oversold (BCRX) - NasdaqJune 29, 2025 | nasdaq.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Lowered to "Buy" Rating by Wall Street ZenJune 29, 2025 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Lowered by Wall Street ZenJune 28, 2025 | marketbeat.comBioCryst to Sell European Orladeyo Business for Up to $264 MillionJune 27, 2025 | marketwatch.comBioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - NasdaqJune 27, 2025 | nasdaq.comBioCryst sells European Orladeyo business in $264M dealJune 27, 2025 | bizjournals.comBioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays BearishJune 27, 2025 | msn.comBioCryst to sell European Orladeyo business for up to $264MJune 27, 2025 | msn.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Time to Buy?June 27, 2025 | marketbeat.comBioCryst Pharmaceuticals (BCRX) Projects Strong Cash Position by 2027 | BCRX Stock NewsJune 27, 2025 | gurufocus.comBioCryst Pharmaceuticals (BCRX) to Divest European Orladeyo Business for $264MJune 27, 2025 | gurufocus.comBioCryst Sells European ORLADEYO Business for $264MJune 27, 2025 | tipranks.comBioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 MillionJune 27, 2025 | globenewswire.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given Buy Rating at Needham & Company LLCJune 27, 2025 | americanbankingnews.comBCRX BioCryst Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives Buy Rating from Needham & Company LLCJune 25, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 22, 2025 | marketbeat.comBioCryst Pharmaceuticals Inc (BCRX) Announces Promising Long-term Data for ORLADEYO in HAE ...June 16, 2025 | gurufocus.comBioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACIJune 16, 2025 | globenewswire.comORLADEYO® (berotralstat) Approved in ColombiaJune 13, 2025 | globenewswire.comCantor Fitzgerald Weighs in on BCRX FY2026 EarningsJune 10, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European CountriesJune 7, 2025 | finanznachrichten.deBioCryst Achieves Reimbursement for ORLADEYO Across all Major European CountriesJune 6, 2025 | globenewswire.comBioCryst Extends Consulting Agreement with Former CFOJune 4, 2025 | tipranks.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comMackenzie Financial Corp Acquires 55,535 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)June 3, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 1-Year High - Still a Buy?June 2, 2025 | marketbeat.comBioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical ImmunologyJune 2, 2025 | globenewswire.comBioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All AgesMay 30, 2025 | globenewswire.comDrugmaker targets younger patients as revenue balloonsMay 29, 2025 | bizjournals.comMillennium Management LLC Trims Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)May 29, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 29, 2025 | marketbeat.comBank of America Corp DE Sells 261,127 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)May 28, 2025 | marketbeat.comBioCryst to Present at Upcoming Investor ConferencesMay 27, 2025 | globenewswire.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Reduced by Voloridge Investment Management LLCMay 27, 2025 | marketbeat.comWoodline Partners LP Makes New $3.39 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)May 27, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Man Group plcMay 27, 2025 | marketbeat.comNuveen Asset Management LLC Sells 1,395,503 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)May 25, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Raised by Two Sigma Advisers LPMay 24, 2025 | marketbeat.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.350.90▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼317▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RGEN News Today MDGL News Today HALO News Today IONS News Today ALKS News Today LGND News Today FOLD News Today CLDX News Today INVA News Today DVAX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
